FIELD: medicine.
SUBSTANCE: invention refers to neurology and therapy and aims at preventing human neurodegenerative disorders and diseases. Synthetic tetrapeptide HAEE, or its pharmaceutically acceptable salts, or complexes, or mixtures thereof are used to protect the function of human neurons to secrete substance (4S,7S,10S,13S)-4-((1H-imidazol-4-yl)methyl)-13-carbamoyl-10-(2-carboxyethyl)-7-methyl-2,5,8,11-tetraoxo-3,6,9,12-tetraazagexadecane-16-acid (SRFM).
EFFECT: use of the invention provides the possibility of preventing neurodegenerative disorders and diseases associated with partial or complete loss of SRFM secretion by neurons under the effect of neurotoxic substances, which leads to a significant drop in the level of SRFM secretion in blood compared to the physiological norm.
15 cl, 2 dwg, 9 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HAEE SYNTHETIC TETRAPEPTIDE AND DERIVATIVES THEREOF INTENDED FOR HUMAN NEURON FUNCTION RECOVERY | 2023 |
|
RU2822603C1 |
| PHYSIOLOGICALLY ACTIVE SUBSTANCE SRFM AS BLOOD BIOMARKER FOR DIAGNOSING HUMAN NEURODEGENERATIVE DISORDERS AND DISEASES | 2023 |
|
RU2822604C1 |
| METHOD FOR TREATING NEURODEGENERATIVE DISEASES | 2021 |
|
RU2777871C1 |
| PHARMACEUTICAL COMPOSITION BASED ON HAEE PEPTIDE FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2709539C1 |
| HAEE PEPTIDE MAGNESIUM COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784746C1 |
| HAEE PEPTIDE COPPER COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784732C1 |
| PEPTIDE CALCIUM COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2785354C1 |
| HAEE PEPTIDE ZINC COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784319C1 |
| AMMONIUM SALT OF HAEE PEPTIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784249C1 |
| METHODS AND REAGENTS FOR IMPROVEMENT OF DETECTING AMYLOID BETA-PEPTIDES | 2010 |
|
RU2554774C2 |
